Servier Pharmaceuticals shared a post on LinkedIn:
“Today, we received a positive CHMP opinion from the European Medicines Agency for our targeted therapy for Grade 2 IDH-mutant glioma.
If approved, this would mark the first significant treatment breakthrough for glioma in over two decades in the EU.
This milestone underscores our commitment to providing options for patients and their families and drive progress for all affected by glioma. Learn more about this news.”
More posts featuring Servier Pharmaceuticals.